Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 15,000 ordinary shares of the company on June 24, 2025, for $14.00 each, totaling $210,000. The transaction comes as the stock has shown strong momentum, delivering a 51% return over the past year. According to InvestingPro analysis, analysts maintain a strong buy consensus with price targets ranging from $26 to $38.
On the same day, Accardi also exercised options to acquire 15,000 ordinary shares at a price of $3.85, for a total value of $57,750. Following these transactions, Accardi directly owns 216,485 ordinary shares of Centessa Pharmaceuticals, a company currently valued at $1.9 billion. The company maintains a strong liquidity position with a current ratio of 14.37, and InvestingPro rates its overall financial health as "Fair."
The sale was executed under a Rule 10b5-1 trading plan adopted on February 14, 2025. Want deeper insights into insider trading patterns and their implications? InvestingPro offers comprehensive analysis with 6 additional ProTips about CNTA’s financial position and market performance.
In other recent news, Centessa Pharmaceuticals has announced the appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025. This executive change was disclosed in a recent SEC filing. Meanwhile, Piper Sandler has maintained its Overweight rating on Centessa Pharmaceuticals with a price target of $38.00. The firm remains optimistic about the company’s orexin 2 receptor (OX2R) agonist treatments, with key data from the Phase 2 CRYSTAL-1 study expected later this year. Additionally, BMO Capital Markets reiterated its Outperform rating on Centessa with a price target of $35.00, highlighting the potential of ORX750 for treating narcolepsy and idiopathic hypersomnia. BMO Capital Markets expresses confidence in the drug’s Phase II trials, estimating an 80% probability of success. Centessa’s pipeline also includes other orexin agonist programs that could expand its market reach. Investors are closely watching upcoming data releases, which could validate the analysts’ positive outlook on Centessa Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.